Results 11 to 20 of about 41,377 (182)

Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China [PDF]

BMJ Open Respiratory Research
Background While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang, Hui Yang, Yi Zhang, Jia Li, Han Wu, Xintong Zhang, Zhuoling An, Yuezhen Zhu, Chunguo Jiang, Wanying Chen   +9 more
doaj   +2 more sources

Severe HCoV‐OC43 Pneumonia in a 25‐Year‐Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation [PDF]

The Clinical Respiratory Journal
Background We report the case of a 25‐year‐old woman with a history of acute lymphoblastic leukemia who developed progressive dyspnea and fever following allogeneic hematopoietic stem cell transplantation.
Mingzhou Zhang, Ting Tang, Mingxia Zheng, Menglin Luo, Zhi Xu, Guansong Wang   +5 more
doaj   +2 more sources

Awareness on current status of usage of ritonavir in the management of covid among dental students

Journal of Advanced Pharmaceutical Technology & Research, 2022
Ritonavir's pharmacodynamics raise questions regarding whether medication concentrations high enough to block the SARS-CoV-2 proteases can be obtained. Ritonavir may have a therapeutic benefit at any stage of the disease, although pharmacodynamic issues ...
Jagadheeswari Ramamoorthy, Dhanraj Ganapathy, Kiran Kumar Pandurangan, Nabeel Ahmed, Subhabrata Maiti   +4 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Clinical Case Reports, 2020
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that
Hayato Koba, Taro Yoneda, Tomoya Kaneda, Tsukasa Ueda, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +1 more source

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

Drugs in Context, 2023
Background: Nirmatrelvir/ritonavir is authorized for the treatment of COVID-19 but has several contraindications and potential drug–drug interactions (pDDIs) due to ritonavir-induced irreversible inhibition of cytochrome P450 3A4.
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann   +9 more
doaj   +1 more source

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]

Терапевтический архив, 2019
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk   +11 more
doaj   +1 more source

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19).
Ji-Won Kim, Eun Jin Kim, Hyun Hee Kwon, Chi Young Jung, Kyung Chan Kim, Jung-Yoon Choe, Hyo-Lim Hong   +6 more
doaj   +1 more source